BusinessAsklepios BioPharmaceutical, Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the ClinicBy Nasdaq OMXApr 25, 2018, 12:05 PM UTC